A321550 Stock Overview
A drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TiumBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,705.00 |
| 52 Week High | ₩11,340.00 |
| 52 Week Low | ₩4,700.00 |
| Beta | 0.75 |
| 11 Month Change | -25.67% |
| 3 Month Change | -26.14% |
| 1 Year Change | -33.55% |
| 33 Year Change | -75.43% |
| 5 Year Change | -72.57% |
| Change since IPO | -65.02% |
Recent News & Updates
Shareholder Returns
| A321550 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.5% | -8.1% | 2.9% |
| 1Y | -33.5% | 18.1% | -2.8% |
Return vs Industry: A321550 underperformed the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A321550 underperformed the KR Market which returned -4% over the past year.
Price Volatility
| A321550 volatility | |
|---|---|
| A321550 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A321550 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A321550's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 50 | Huntaek Kim | www.tiumbio.com |
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates.
TiumBio Co., Ltd. Fundamentals Summary
| A321550 fundamental statistics | |
|---|---|
| Market cap | ₩122.45b |
| Earnings (TTM) | -₩15.94b |
| Revenue (TTM) | ₩7.91b |
15.5x
P/S Ratio-7.7x
P/E RatioIs A321550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A321550 income statement (TTM) | |
|---|---|
| Revenue | ₩7.91b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩7.91b |
| Other Expenses | ₩23.85b |
| Earnings | -₩15.94b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -612.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -201.48% |
| Debt/Equity Ratio | 42.4% |
How did A321550 perform over the long term?
See historical performance and comparison